EnChannel Medical, a Guangzhou-based electrophysiology platform company, has reportedly secured RMB 200 million (USD 28 million) in a Series A financing round. The round was co-led by Lapam Capital and Lilly Asia Ventures, with the proceeds earmarked for enhancing clinical filings, commercialization efforts, and research and development systems within the global electrophysiology field.
Innovations in Atrial Fibrillation Treatment
Founded in 2020, EnChannel is dedicated to the development of atrial fibrillation treatment products. The company is known for its first-in-class “four-dimensional cardiac mapping system,” which integrates magnetoelectric positioning contact mapping technology and magnetoelectric positioning non-contact mapping technology. This innovative system enables real-time mapping of arrhythmia mechanisms during electrophysiological surgeries, offering a significant advancement in the field.
China’s Growing Electrophysiology Market
China is poised to become the world’s largest electrophysiological market. The latest statistical data indicates that in 2021, the number of cardiac electrophysiological surgeries in China surpassed 210,000, including nearly 90,000 atrial fibrillation ablation units. This number is projected to reach 574,600 cases by 2025. In line with this growth, the sales revenue of various electrophysiological manufacturers in the Chinese market exceeded RMB 8 billion in 2021 and is expected to increase to RMB 15.726 billion by 2025, highlighting the immense potential and demand for advanced electrophysiology solutions.-Fineline Info & Tech
